Researchers at the University of Sussex, in collaboration with scientists from different institutes worldwide, have identified a blood test capable of early diagnosis of the most aggressive form of brain tumor. The technology has the potential to save lives. Lead author Professor Georgios Giamas and his team have identified distinctive biomarkers (molecules that act as signs of normal processes, diseases, or responses to treatment) within patient blood samples, which could signal the presence of glioblastoma, one of the most aggressive forms of brain tumor.

The study published in Cell Reports Medicine investigated whether a simple blood test—analyzing the cargo of tiny particles called small extracellular vesicles (sEVs) that are released by cells into the bloodstream—could accurately detect and classify these tumors.

More than 11,000 people are diagnosed with a primary brain tumor in the U.K. each year. Glioblastoma is the most common high grade primary brain tumor in adults, which means it can grow and spread exceptionally quickly. Currently, diagnosing glioma often requires risky brain surgery.

Horner’s syndrome (HS) occurs when there is interruption of the oculosympathetic pathway (OSP). This article reviews the anatomy of the OSP and clinical findings associated with lesions located at various positions along this pathway. The imaging findings of lesions associated with HS at various levels of the OSP, classified as preganglionic HS (first-and second-order neuron HS) or postganglionic HS (third-order neuron HS), are demonstrated.

The authors discovered that training mice to exhibit a placebo effect with one type of pain produces marked relief of several different types of pain, including pain caused by injury.

To establish that the native opioid peptides actually drive pain relief, similar to opioid painkillers such as morphine, the researchers employed a light-activated drug developed in Banghart’s lab called PhNX, for photoactivatable naloxone. Naloxone, also known as Narcan, is the medicine used to reverse opioid overdoses by blocking opioid receptors. Using light, they were able to precisely control the site and timing of opioid signaling interference. Using PhNX, the scienists found that both morphine-induced pain relief and placebo pain relief rely on opioid signaling in the vlPAG brain region.

Co-first author: “We essentially trained a mouse brain to create its own broad-spectrum painkillers on demand, precisely where they are needed to treat pain, without the off-target effects of opioid-based painkillers.”

“These results increase the translational relevance of rodent placebo models to clinical contexts, in which patients’ prior experiences with drugs and treatment settings can generalize to broader expectations of improvement,” the researchers conclude in their paper. ScienceMission sciencenewshighlights.

---

Placebo effects, in which patients experience relief without therapeutic treatment, increasingly have been considered as potentially powerful clinical treatments for ailments such as depression and pain. Yet the neurological mechanisms underlying such processes are not fully understood.

Now, a multi-institutional team has pinpointed the brain circuitry responsible for placebo pain relief. Their findings, reported in the journal Neuron, describe brain regions that support placebo effects and identify sites where endogenous opioid neuropeptides (commonly referred to as endorphins) provide signals that are critical for placebo pain relief.

Functional unblinding was common in most psychedelic randomized clinical trials for psychiatric disorders, with 70% correctly identifying treatment allocation, raising concerns for trial validity.

---

Question What is the prevalence of blinding integrity assessment and the extent of functional unblinding in psychedelic randomized clinical trials (RCTs) for psychiatric disorders?

Findings Of 112 RCTs identified, 29.5% (n = 33) evaluated blinding integrity. Functional unblinding was substantial: psilocybin, lysergic acid diethylamide (LSD), and ayahuasca studies frequently reported blinding failure values of more than 90% among participants and raters; inert placebo-controlled 3,4-methylenedioxymethamphetamine (MDMA) trials exceeded 85%; ketamine trials rarely assessed blinding (17.9%) but showed improved preservation with midazolam vs saline controls.

Meaning Functional unblinding is pervasive in psychedelic RCTs, underscoring the need for standardized assessment methods and improved trial designs to ensure valid efficacy evaluations.